These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12036347)

  • 1. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
    Naumann T; Matter H
    J Med Chem; 2002 Jun; 45(12):2366-78. PubMed ID: 12036347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
    Ducrot P; Legraverend M; Grierson DS
    J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
    Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
    Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting malaria with specific CDK inhibitors.
    Geyer JA; Prigge ST; Waters NC
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.
    Matter H; Schwab W
    J Med Chem; 1999 Nov; 42(22):4506-23. PubMed ID: 10579815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.
    Wu SY; McNae I; Kontopidis G; McClue SJ; McInnes C; Stewart KJ; Wang S; Zheleva DI; Marriage H; Lane DP; Taylor P; Fischer PM; Walkinshaw MD
    Structure; 2003 Apr; 11(4):399-410. PubMed ID: 12679018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
    Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
    J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
    Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
    J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
    Deng Z; Chuaqui C; Singh J
    J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
    Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
    J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
    Jeffrey PD; Tong L; Pavletich NP
    Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
    Keenan SM; Welsh WJ
    J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
    Haesslein JL; Jullian N
    Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.